Discovery of [11C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases-Reference-Cited by-同舟云学术

Discovery of [11C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases

Published:2020-02-26 Issue:5 Volume:63 Page:2411-2425
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Tong Ling¹^ORCID,Li Wenping²,Lo Michael Man-Chu³,Gao Xiaolei³,Wai Jenny Miu-Chen¹,Rudd Michael¹,Tellers David¹^ORCID,Joshi Aniket²,Zeng Zhizhen²,Miller Patricia²,Salinas Cristian²,Riffel Kerry²,Haley Hyking²,Purcell Mona²,Holahan Marie²,Gantert Liza²,Schubert Jeffrey W.¹,Jones Kristen¹,Mulhearn James¹,Egbertson Melissa¹,Meng Zhaoyang¹,Hanney Barbara¹,Gomez Robert¹,Harrison Scott T.¹,McQuade Paul²,Bueters Tjerk⁴,Uslaner Jason⁵^ORCID,Morrow John⁵,Thomson Fiona⁵^ORCID,Kong Jongrock⁶,Liao Jing⁶,Selyutin Oleg³,Bao Jianming³,Hastings Nicholas B.⁵,Agrawal Sony⁵,Magliaro Brian C.⁵,Monsma Frederick J.⁵,Smith Michelle D.⁵,Risso Stefania⁵,Hesk David⁶,Hostetler Eric²,Mazzola Robert³

Affiliation:

1. Discovery Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States

2. Translational Biomarkers, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States

3. Discovery Chemistry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States

4. Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States

5. Discovery Biology, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States

6. Department of Process Research and Development, Merck & Co., Inc., 126 East Lincoln Avenue Rahway, New Jersey 07065, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01406

Reference33 articles.

1. Dementia Statistics; Alzheimer’s Disease International, 2020; https://www.alz.co.uk/research/statistics (accessed 2019-08-21).

2. Natural history of Alzheimer’s disease

3. Psychosis in Alzheimer’s Disease

4. Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease

5. Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical Evaluation of Dihydropyrazole-Cored Positron Emission Tomography (PET) Ligands for Imaging of Receptor-Interacting Serine/Threonine Protein Kinase 1 (RIPK1) in the Brain;Journal of Medicinal Chemistry;2024-09-11

2. Discovery of 2-Methyl-5-(1H-pyrazol-4-yl)pyridines and Related Heterocycles as Promising M₄ mAChR Positive Allosteric Modulators for the Treatment of Neurocognitive Disorders;Journal of Medicinal Chemistry;2024-07-18

3. PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [¹¹C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator;Journal of Cerebral Blood Flow & Metabolism;2024-03-13

4. Harnessing the Power of C–H Functionalization Chemistry to Accelerate Drug Discovery;Synlett;2024-01-15

5. In vitro evaluation of PET radiotracers for imaging synaptic density, the acetylcholine transporter, AMPA-tarp-γ8 and muscarinic M4 receptors in Alzheimer’s disease;American Journal of Nuclear Medicine and Molecular Imaging;2024